bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S4 from 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Authors: D'Huyvetter Matthias , De Vos Jens , Xavier Catarina , Pruszynski Marek , Sterckx Yann G.J. , Massa Sam , Raes Geert , Caveliers Vicky , Zalutsky Michael R. , Lahoutte Tony , Devoogdt Nick
Published: April 2023

Supplementary Table S4 shows the ex vivo biodistribution of 131I-2Rs15d and [131I]-control in mice with BT474/M1 xenografts.
Supplementary Table S3 from 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Authors: D'Huyvetter Matthias , De Vos Jens , Xavier Catarina , Pruszynski Marek , Sterckx Yann G.J. , Massa Sam , Raes Geert , Caveliers Vicky , Zalutsky Michael R. , Lahoutte Tony , Devoogdt Nick
Published: April 2023

Supplementary Table S3 shows the in vivo biodistribution of 131I-2Rs15d after 1, 4 and 24h in mice with BT474/M1 and SKOV-3 xenografts.
Figure S4 from Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Authors: Shi Puyu , Oh You-Take , Deng Liang , Zhang Guojing , Qian Guoqing , Zhang Shuo , Ren Hui , Wu Grant , Legendre Benjamin , Anderson Emily , Ramalingam Suresh S. , Owonikoko Taofeek K. , Chen Mingwei , Sun Shi-Yong
Published: April 2023

Time-dependent effect of AZD9291 on reducing Mcl-1 levels in PC-9 cells
Supplementary Table 1 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Authors: Hertz Daniel L. , Owzar Kouros , Lessans Sherrie , Wing Claudia , Jiang Chen , Kelly William Kevin , Patel Jai , Halabi Susan , Furukawa Yoichi , Wheeler Heather E. , Sibley Alexander B. , Lassiter Cameron , Weisman Lois , Watson Dorothy , Krens Stefanie D. , Mulkey Flora , Renn Cynthia L. , Small Eric J. , Febbo Phillip G. , Shterev Ivo , Kroetz Deanna L. , Friedman Paula N. , Mahoney John F. , Carducci Michael A. , Kelley Michael J. , Nakamura Yusuke , Kubo Michiaki , Dorsey Susan G. , Dolan M. Eileen , Morris Michael J. , Ratain Mark J. , McLeod Howard L.
Published: April 2023

Number of patients who experienced neuropathy, completed treatment without neuropathy and discontinued treatment early without having neuropathy while on study and within each range of cumulative treatment.
Figure S2 from Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Authors: Shi Puyu , Oh You-Take , Deng Liang , Zhang Guojing , Qian Guoqing , Zhang Shuo , Ren Hui , Wu Grant , Legendre Benjamin , Anderson Emily , Ramalingam Suresh S. , Owonikoko Taofeek K. , Chen Mingwei , Sun Shi-Yong
Published: April 2023

PC-9/3M cell are resistant to AZD9291, CO1686 and erlotinib
Supplementary Figure S4 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Figure S4. A) Survival analysis of the upregulated (11/27) gene signature in high grade BLCA from the Kim, Lindgren, Sjodahl, and TCGA coherts. B) Survival analysis of the upregulated (11/27) gene signature in low grade BLCA from the Kim, Lindgren, and Sjodahl coherts. Upregulated genes associated with poor survival in the TCGA high-grade (log-rank p<0.0041), the Lindgren high grade cohort (log-rank p<0.0298), and in the Sjodahl low-grade cohort (log-rank p<0.0418). (LG=low-grade, HG= high-grade).
Supplementary Figure S1 from Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer
Authors: Vantaku Venkatrao , Dong Jianrong , Ambati Chandrashekar R. , Perera Dimuthu , Donepudi Sri Ramya , Amara Chandra Sekhar , Putluri Vasanta , Ravi Shiva Shankar , Robertson Matthew J. , Piyarathna Danthasinghe Waduge Badrajee , Villanueva Mariana , von Rundstedt Friedrich-Carl , Karanam Balasubramanyam , Ballester Leomar Y. , Terris Martha K. , Bollag Roni J. , Lerner Seth P. , Apolo Andrea B. , Villanueva Hugo , Lee MinJae , Sikora Andrew G. , Lotan Yair , Sreekumar Arun , Coarfa Cristian , Putluri Nagireddy
Published: April 2023

Supplementary Figure S1. A) Quality control of 519 metabolites across three biological replicates of pooled liver sample extracts and run in hydrophilic interaction liquid chromatography (HILIC) positive, HILIC negative, and reverse phase positive ionization modes. B) Quality control (QC) of detected 19 lipids across three biological replicates of pooled sample extracts run in positive and negative ionization modes.
Figure S2 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial
Authors: Mauge Laetitia , Mejean Arnaud , Fournier Laure , Pereira Helena , Etienne-Grimaldi Marie-Christine , Levionnois Emeline , Caty Armelle , Abadie-Lacourtoisie Sophie , Culine Stéphane , Le Moulec Sylvestre , Linassier Claude , Théodore Christine , Ravaud Alain , Albiges Laurence , Grine Abel , Tartour Eric , Milano Gérard , Gille Anne-Sophie , Verkarre Virginie , Helley Dominique , Oudard Stéphane
Published: April 2023

Kaplan-Meier analysis of progression-free survival (PFS; A-D) and overall survival (OS; E-F) according to baseline biomarker levels. HR, hazard ratio; CI, confidence interval.
Figure S1 from Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial
Authors: Mauge Laetitia , Mejean Arnaud , Fournier Laure , Pereira Helena , Etienne-Grimaldi Marie-Christine , Levionnois Emeline , Caty Armelle , Abadie-Lacourtoisie Sophie , Culine Stéphane , Le Moulec Sylvestre , Linassier Claude , Théodore Christine , Ravaud Alain , Albiges Laurence , Grine Abel , Tartour Eric , Milano Gérard , Gille Anne-Sophie , Verkarre Virginie , Helley Dominique , Oudard Stéphane
Published: April 2023

Kaplan-Meier analysis of median (m) overall survival (A) and progression-free survival (A) according to response. HR, hazard ratio; CI, confidence interval.
Supplemental Table S6 from Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer
Authors: Kim Tae Won , Peeters Marc , Thomas Anne , Gibbs Peter , Hool Kristina , Zhang Jianqi , Ang Agnes Lee , Bach Bruce Allen , Price Timothy
Published: April 2023

Analysis of Overall Survival (OS) and Progression-Free Survival (PFS) by Emergent Plasma Mutation Status of BRAF and EGFR
Figure S3 from Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients
Authors: Hogan Daniel J. , Zhu Jay-Jiguang , Diago Oscar R. , Gammon Dawn , Haghighi Ali , Lu Guangrong , Das Asha , Gruber Harry E. , Jolly Douglas J. , Ostertag Derek
Published: April 2023

Figure S3
Supplementary data_310718 from Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer
Authors: Sipeky Csilla , Gao Ping , Zhang Qin , Wang Liang , Ettala Otto , Talala Kirsi M. , Tammela Teuvo L.J. , Auvinen Anssi , Wiklund Fredrik , Wei Gong-Hong , Schleutker Johanna
Published: April 2023

Supplementary Table 1. Clinical characteristics of Finnish prostate cancer patients Supplementary Table 2. Tumour Stage Group (TSG) definitions Supplementary Table 3. Follow-up characteristics used in survival analyses of Finnish prostate cancer patients Supplementary Table 4. Primer sequences used in quantitative RT-PCR reactions Supplementary Table 5. Assessment of PrCa risk due to the combination of HOXB13 T and CIP2A T in dual carriers relative to the risk in non-carriers Supplementary Table 6 Time-to-PrCa event of HOXB13 rs138213197 and CIP2A rs2278911 Supplementary Table 7 Association of HOXB13 G84E and CIP2A R229Q carrier status and clinical features of prostate cancer subgroups Supplementary Table 8. Association of HOXB13 and CIP2A carrier status and combined modality stage of prostate cancer patients according to ERSPC Supplementary Table 9. P-values for Figure1, Figure 2 and Supplementary figure 2. Supplementary figure 1. Higher mRNA expression pattern of HOXB13-CIP2A correlated with increased risk of prostate cancer biochemical recurrence. Supplementary figure 2. Effects of HOXB13 G84E and CIP2A R229Q variants on prostate cell migration. Supplementary figure 3. ChIP-qPCR in VCaP cell line Supplementary figure 4. Overexpression of HOXB13 G84E and CIP2A R229Q variants promotes cell proliferation.
Supplement Table 1 from Auranofin Protects Intestine against Radiation Injury by Modulating p53/p21 Pathway and Radiosensitizes Human Colon Tumor
Authors: Nag Dhrubajyoti , Bhanja Payel , Riha Randal , Sanchez-Guerrero Giselle , Kimler Bruce F. , Tsue Terance T. , Lominska Chris , Saha Subhrajit
Published: April 2023

mRNA expression of UPR downstream proapoptotic molecule
FigureS1 from Auranofin Protects Intestine against Radiation Injury by Modulating p53/p21 Pathway and Radiosensitizes Human Colon Tumor
Authors: Nag Dhrubajyoti , Bhanja Payel , Riha Randal , Sanchez-Guerrero Giselle , Kimler Bruce F. , Tsue Terance T. , Lominska Chris , Saha Subhrajit
Published: April 2023

Supplement FigureS1
Supplemental Tables from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Authors: Bacac Marina , Colombetti Sara , Herter Sylvia , Sam Johannes , Perro Mario , Chen Stanford , Bianchi Roberta , Richard Marine , Schoenle Anne , Nicolini Valeria , Diggelmann Sarah , Limani Florian , Schlenker Ramona , Hüsser Tamara , Richter Wolfgang , Bray-French Katharine , Hinton Heather , Giusti Anna Maria , Freimoser-Grundschober Anne , Lariviere Laurent , Neumann Christiane , Klein Christian , Umaña Pablo
Published: April 2023

Supplemental Table 1. Overview of CD20-targeting T-cell bispecific molecules evaluated in the current study. Supplemental Table 2. Tumor cell lines and EC50 values of tumor cell lysis. Supplemental Table 3. Assessment of the activity in ex vivo primary tumor samples derived from aggressive lymphoma and leukemia patients. Supplemental Table 4. Absolute values of cytokines measured by multiplex analysis of blood samples reported as heatmap in Figure 3e, 4b, 5d, and 6b. Supplemental Table 5. Average score of perivascular CD3 positive T-cells in the lung (assessed by blinded pathologist analysis) referring to T-cell staining of lungs from tumor-bearing, HSC NSG mice 7 days after the first treatment and 24 h after the second treatment (treatment groups are indicated on Figure 6D panels).
Figure S2 from Auranofin Protects Intestine against Radiation Injury by Modulating p53/p21 Pathway and Radiosensitizes Human Colon Tumor
Authors: Nag Dhrubajyoti , Bhanja Payel , Riha Randal , Sanchez-Guerrero Giselle , Kimler Bruce F. , Tsue Terance T. , Lominska Chris , Saha Subhrajit
Published: April 2023

Supplement Figure S2
Figure S5 from Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46
Authors: Liu Yen-Nien , Niu Shaoxi , Chen Wei-Yu , Zhang Qingfu , Tao Yulei , Chen Wei-Hao , Jiang Kuo-Ching , Chen Xufeng , Shi Huaiyin , Liu Aijun , Li Jinhang , Li Yanjing , Lee Yi-Chao , Zhang Xu , Huang Jiaoti
Published: April 2023

Supplementary Figure S5
Figure S3 from Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46
Authors: Liu Yen-Nien , Niu Shaoxi , Chen Wei-Yu , Zhang Qingfu , Tao Yulei , Chen Wei-Hao , Jiang Kuo-Ching , Chen Xufeng , Shi Huaiyin , Liu Aijun , Li Jinhang , Li Yanjing , Lee Yi-Chao , Zhang Xu , Huang Jiaoti
Published: April 2023

Supplementary Figure S3
Figure S1 from Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46
Authors: Liu Yen-Nien , Niu Shaoxi , Chen Wei-Yu , Zhang Qingfu , Tao Yulei , Chen Wei-Hao , Jiang Kuo-Ching , Chen Xufeng , Shi Huaiyin , Liu Aijun , Li Jinhang , Li Yanjing , Lee Yi-Chao , Zhang Xu , Huang Jiaoti
Published: April 2023

Supplementary Figure S1
Supplementary legends and methods from Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
Authors: Dankner Matthew , Lajoie Mathieu , Moldoveanu Dan , Nguyen Tan-Trieu , Savage Paul , Rajkumar Shivshankari , Huang Xiu , Lvova Maria , Protopopov Alexei , Vuzman Dana , Hogg David , Park Morag , Guiot Marie-Christine , Petrecca Kevin , Mihalcioiu Catalin , Watson Ian R. , Siegel Peter M. , Rose April A.N.
Published: April 2023

Supplementary legends and methods
Supplementary Data from Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Authors: Di Cosimo Serena , Appierto Valentina , Pizzamiglio Sara , Tiberio Paola , Iorio Marilena V. , Hilbers Florentine , de Azambuja Evandro , de la Peña Lorena , Izquierdo Miguel , Huober Jens , Baselga José , Piccart Martine , de Braud Filippo G. , Apolone Giovanni , Verderio Paolo , Daidone Maria Grazia
Published: April 2023

Including legends of Suppl Figures introduced on Feb 20th
Supplementary Figure S2 from Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Authors: Keysar Stephen B. , Eagles Justin R. , Miller Bettina , Jackson Brian C. , Chowdhury Farshad N. , Reisinger Julie , Chimed Tugs-Saikhan , Le Phuong N. , Morton John J. , Somerset Hilary L. , Varella-Garcia Marileila , Tan Aik-Choon , Song John I. , Bowles Daniel W. , Reyland Mary E. , Jimeno Antonio
Published: April 2023

Fig. S2. (A) Metaphase spread of the cell line AG09391 hybridized with the NFIB(SG)/MTFR2(SR) FISH fusion probe set. The MTFR2 probe recognized homology with the chromosome 6q terminal band, compatible with mapping at 6q23.3; the NFIB probe recognized homology with the chromosome 9p terminal band, compatible with mapping at 9p22.3. Normal CUSG004 patient tissue hybridized with the NFIB(SG)/MTFR2(SR) FISH fusion probe set, showing negative pattern. CUSG004 patient tumor tissue (F0) and PDX tumor tissue (F1, F2, F5) hybridized with the NFIB(SG)/MTFR2(SR) FISH fusion probe set, with patient tumor and PDX tissue showing positive pattern. (B) CUSG005 patient (F0), CUSG005 PDX (F1), and CUSG006 PDX (F2) tumor tissue hybridized with the NFIB(SG)/MTFR2(SR) FISH fusion probe set, with CUSG005 tissue showing positive pattern and CUSG006 tissue a negative pattern. Our FISH probes also detected the MYB-NFIB fusion in the CUSG005 tumor and was likely due to the close proximity (<1Mbp) of MTFR2 and MYB on the q arm of chromosome 6 Arrows indicate fused signals.
Supplementary Figure S1 from Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Authors: Keysar Stephen B. , Eagles Justin R. , Miller Bettina , Jackson Brian C. , Chowdhury Farshad N. , Reisinger Julie , Chimed Tugs-Saikhan , Le Phuong N. , Morton John J. , Somerset Hilary L. , Varella-Garcia Marileila , Tan Aik-Choon , Song John I. , Bowles Daniel W. , Reyland Mary E. , Jimeno Antonio
Published: April 2023

Fig. S1. (A) Passaging times for engrafted PDX cases (passage 0 = time from implantation of patient tissue to an established tumor >1,500 mm3). We next analyzed the amount of time between cohort implantation (5 mice, 10 implantations) and passaging to a fresh cohort upon tumors reaching >1,500 mm3 in size. Initial engraftment times between patient tissue implantation (F0 generation) and harvesting tumors in the first cohort of mice (F1 generation) ranged between 140 days (CUSG006) and 409 days (CUSG004). The time between passages for the ACC model CUSG004 decreased from 409 to 84 days from the F1 generation to the F6 generation, while CUSG005 (ACC) required >300 days for its first three passages (F0-F3). MEC PDX generations (CUSG006, -007) remained relatively constant. (B) Cancer related (COSMIC) mutations in SGC cases.
Supplementary Figure S3 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
Authors: González-González Adrián , Muñoz-Muela Esperanza , Marchal Juan A. , Cara Francisca E. , Molina Maria P. , Cruz-Lozano Marina , Jiménez Gema , Verma Akanksha , Ramírez Alberto , Qian Wei , Chen Wen , Kozielski Anthony J. , Elemento Olivier , Martín-Salvago María D. , Luque Rafael J. , Rosa-Garrido Carmen , Landeira David , Quintana-Romero María , Rosato Roberto R. , García Maria A. , Ramirez-Tortosa Cesar L. , Kim Hanna , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Lorente Jose A. , Sánchez-Rovira Pedro , Chang Jenny C. , Granados-Principal Sergio
Published: April 2023

Supplementary Figure 3. Screening of non-canonical molecular pathways and OncoPrint analysis of the eight-gene signature.
Figure S7 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S7 shows the IGF2 signaling pathways on different breast cancer cells exposed to the CM from distinct CAFs
Figure S6 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S6 shows IGF2 levels in different CAFs alone or co-cultured with MDA-MB-436cells
Figure S3 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S3 shows metastatic lesions and IGF2 expression of the CAFs-tumors xenografts in vivo
Figure S2 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S2 shows mCAFs have a stronger capacity to promote breast cancer cell proliferation and are resistant to chemotherapy
Table S3 from The Hsp27-Mediated IkBα-NFκB Signaling Axis Promotes Radiation-Induced Lung Fibrosis
Authors: Kim Jee-Youn , Jeon Seulgi , Yoo Young Jo , Jin Hee , Won Hee Yeon , Yoon Kyeonghee , Hwang Eun Sook , Lee Yoon-Jin , Na Younghwa , Cho Jaeho , Lee Yun-Sil
Published: April 2023

The clinicopathologic characteristics of lung cancer patients
Supplemental legend from Anagrelide for Gastrointestinal Stromal Tumor
Authors: Pulkka Olli-Pekka , Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Mpindi John-Patrick , Tynninen Olli , Icay Katherine , Cervera Alejandra , Keskitalo Salla , Murumägi Astrid , Kulesskiy Evgeny , Laaksonen Maria , Wennerberg Krister , Varjosalo Markku , Laakkonen Pirjo , Lehtonen Rainer , Hautaniemi Sampsa , Kallioniemi Olli , Schöffski Patrick , Sihto Harri , Joensuu Heikki
Published: April 2023

Supplemental legend
Figure S5 from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Authors: Liu Li , Bai Xue , Wang Jian , Tang Xin-Ran , Wu De-Hua , Du Sha-Sha , Du Xiu-Ju , Zhang Yao-Wei , Zhu Hong-Bo , Fang Yuan , Guo Ze-Qin , Zeng Qin , Guo Xue-Jun , Liu Zhu , Dong Zhong-Yi
Published: April 2023

The outcome-based cutpoint of TMB and CNA as continuous variables in three ICI treated cohort analyzed by X-tile software. Kaplan-Meier curves of survival according to the cutpoints of TMB and CNA calculated by X-tile software in (A) NSCLC ICI, (B) SKCM ICI, and (C) Dana-Farber ICI cohorts; (D) The summary of subpopulation cutpoints of TMB and CNA in the above three cohorts. Hi, high; Lo, low.
Table S5 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Authors: Aloia Andrea , Müllhaupt Daniela , Chabbert Christophe D. , Eberhart Tanja , Flückiger-Mangual Stefanie , Vukolic Ana , Eichhoff Ossia , Irmisch Anja , Alexander Leila T. , Scibona Ernesto , Frederick Dennie T. , Miao Benchun , Tian Tian , Cheng Chaoran , Kwong Lawrence N. , Wei Zhi , Sullivan Ryan J. , Boland Genevieve M. , Herlyn Meenhard , Flaherty Keith T. , Zamboni Nicola , Dummer Reinhard , Zhang Gao , Levesque Mitchell P. , Krek Wilhelm , Kovacs Werner J.
Published: April 2023

Table S5, related to Figure S5C
Table S3 from Functional Genomics Identifies Hepatitis-Induced STAT3–TYRO3–STAT3 Signaling as a Potential Therapeutic Target of Hepatoma
Authors: Tsai Chia-Liang , Chang Jeng-Shou , Yu Ming-Chin , Lee Chern-Horng , Chen Tse-Ching , Chuang Wen-Yu , Kuo Wei-Liang , Lin Chen-Chun , Lin Shi-Ming , Hsieh Sen-Yung
Published: April 2023

Summary of the xenograft and tumor-sphere formation assays
Table S2 from Functional Genomics Identifies Hepatitis-Induced STAT3–TYRO3–STAT3 Signaling as a Potential Therapeutic Target of Hepatoma
Authors: Tsai Chia-Liang , Chang Jeng-Shou , Yu Ming-Chin , Lee Chern-Horng , Chen Tse-Ching , Chuang Wen-Yu , Kuo Wei-Liang , Lin Chen-Chun , Lin Shi-Ming , Hsieh Sen-Yung
Published: April 2023

Protein- expression profiles of the RTK family members in the hepatocytes and hepatoma cells
Supplementary Figures from Functional Genomics Identifies Hepatitis-Induced STAT3–TYRO3–STAT3 Signaling as a Potential Therapeutic Target of Hepatoma
Authors: Tsai Chia-Liang , Chang Jeng-Shou , Yu Ming-Chin , Lee Chern-Horng , Chen Tse-Ching , Chuang Wen-Yu , Kuo Wei-Liang , Lin Chen-Chun , Lin Shi-Ming , Hsieh Sen-Yung
Published: April 2023

Supplemental Figure S2 to S11
Clean_Spplementary Data_CCR_18_1580R1 from Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
Authors: Berberich Anne , Kessler Tobias , Thomé Carina M. , Pusch Stefan , Hielscher Thomas , Sahm Felix , Oezen Iris , Schmitt Lara-Marie , Ciprut Sara , Hucke Nanina , Ruebmann Petra , Fischer Manuel , Lemke Dieter , Breckwoldt Michael O. , von Deimling Andreas , Bendszus Martin , Platten Michael , Wick Wolfgang
Published: April 2023

Supplementary Methods
Supplemental Data from Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer
Authors: Lieu Christopher H. , Golemis Erica A. , Serebriiskii Ilya G. , Newberg Justin , Hemmerich Amanda , Connelly Caitlin , Messersmith Wells A. , Eng Cathy , Eckhardt S. Gail , Frampton Garrett , Cooke Matthew , Meyer Joshua E.
Published: April 2023

Supplemental Table 1 and Figures 1 and 2
Supplementary Data from Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites
Authors: Nassar Amin H. , Umeton Renato , Kim Jaegil , Lundgren Kevin , Harshman Lauren , Van Allen Eliezer M. , Preston Mark , Dong Fei , Bellmunt Joaquim , Mouw Kent W. , Choueiri Toni K. , Sonpavde Guru , Kwiatkowski David J.
Published: April 2023

Flow diagram for the study.
Table S6 from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Authors: Vaubel Rachael A. , Tian Shulan , Remonde Dioval , Schroeder Mark A. , Mladek Ann C. , Kitange Gaspar J. , Caron Alissa , Kollmeyer Thomas M. , Grove Rebecca , Peng Sen , Carlson Brett L. , Ma Daniel J. , Sarkar Gobinda , Evers Lisa , Decker Paul A. , Yan Huihuang , Dhruv Harshil D. , Berens Michael E. , Wang Qianghu , Marin Bianca M. , Klee Eric W. , Califano Andrea , LaChance Daniel H. , Eckel-Passow Jeanette E. , Verhaak Roel G. , Sulman Erik P. , Burns Terry C. , Meyer Fredrick B. , O'Neill Brian P. , Tran Nhan L. , Giannini Caterina , Jenkins Robert B. , Parney Ian F. , Sarkaria Jann N.
Published: April 2023

Molecular subtype, MGMT methylation, expressed fusions
Table S2 from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Authors: Vaubel Rachael A. , Tian Shulan , Remonde Dioval , Schroeder Mark A. , Mladek Ann C. , Kitange Gaspar J. , Caron Alissa , Kollmeyer Thomas M. , Grove Rebecca , Peng Sen , Carlson Brett L. , Ma Daniel J. , Sarkar Gobinda , Evers Lisa , Decker Paul A. , Yan Huihuang , Dhruv Harshil D. , Berens Michael E. , Wang Qianghu , Marin Bianca M. , Klee Eric W. , Califano Andrea , LaChance Daniel H. , Eckel-Passow Jeanette E. , Verhaak Roel G. , Sulman Erik P. , Burns Terry C. , Meyer Fredrick B. , O'Neill Brian P. , Tran Nhan L. , Giannini Caterina , Jenkins Robert B. , Parney Ian F. , Sarkaria Jann N.
Published: April 2023

Patient characteristics of viable PDX lines
Supplementary Figure S6 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Authors: Fernández-Nogueira Patricia , Mancino Mario , Fuster Gemma , López-Plana Anna , Jauregui Patricia , Almendro Vanesa , Enreig Estel , Menéndez Silvia , Rojo Federico , Noguera-Castells Aleix , Bill Anke , Gaither L. Alex , Serrano Laia , Recalde-Percaz Leire , Moragas Núria , Alonso Raul , Ametller Elisabet , Rovira Ana , Lluch Ana , Albanell Joan , Gascon Pere , Bragado Paloma
Published: April 2023

FGFR2, FGF5, c-Src, phospho-c-Src and phospho-HER2 correlation in breast cancer patients
eTable2 from Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy
Authors: Sjöström Martin , Chang S. Laura , Fishbane Nick , Davicioni Elai , Hartman Linda , Holmberg Erik , Feng Felix Y. , Speers Corey W. , Pierce Lori J. , Malmström Per , Fernö Mårten , Karlsson Per
Published: April 2023

MET141 genelist
Supplementary Figures from Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy
Authors: Sjöström Martin , Chang S. Laura , Fishbane Nick , Davicioni Elai , Hartman Linda , Holmberg Erik , Feng Felix Y. , Speers Corey W. , Pierce Lori J. , Malmström Per , Fernö Mårten , Karlsson Per
Published: April 2023

Supplementary Figures
Supplemental Table 3 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Authors: Rotow Julia K. , Gui Philippe , Wu Wei , Raymond Victoria M. , Lanman Richard B. , Kaye Frederic J. , Peled Nir , Fece de la Cruz Ferran , Nadres Brandon , Corcoran Ryan B. , Yeh Iwei , Bastian Boris C. , Starostik Petr , Newsom Kimberly , Olivas Victor R. , Wolff Alexander M. , Fraser James S. , Collisson Eric A. , McCoach Caroline E. , Camidge D. Ross , Pacheco Jose , Bazhenova Lyudmila , Li Tianhong , Bivona Trever G. , Blakely Collin M.
Published: April 2023

The MET F1200 residue is conserved across multiple tyrosine kinases
Supplemental Figure S4 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Authors: Rotow Julia K. , Gui Philippe , Wu Wei , Raymond Victoria M. , Lanman Richard B. , Kaye Frederic J. , Peled Nir , Fece de la Cruz Ferran , Nadres Brandon , Corcoran Ryan B. , Yeh Iwei , Bastian Boris C. , Starostik Petr , Newsom Kimberly , Olivas Victor R. , Wolff Alexander M. , Fraser James S. , Collisson Eric A. , McCoach Caroline E. , Camidge D. Ross , Pacheco Jose , Bazhenova Lyudmila , Li Tianhong , Bivona Trever G. , Blakely Collin M.
Published: April 2023

KRAS amplification and/or KRAS G12D mutation in METex14-mutated NSCLC with resistance to crizotinib
Table S3 from Genetic Ancestry–dependent Differences in Breast Cancer–induced Field Defects in the Tumor-adjacent Normal Breast
Authors: Nakshatri Harikrishna , Kumar Brijesh , Burney Heather N. , Cox Mary L. , Jacobsen Max , Sandusky George E. , D'Souza-Schorey Crislyn , Storniolo Anna Maria V.
Published: April 2023

Tumor versus NAT comparisons
Supplementary Data from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Authors: Kwon Minsuk , Kim Chang Gon , Lee Hoyoung , Cho Hyunsoo , Kim Youngun , Lee Eung Chang , Choi Seong Jin , Park Junsik , Seo In-Ho , Bogen Bjarne , Song Ik-Chan , Jo Deog-Yeon , Kim Jin Seok , Park Su-Hyung , Choi Inhak , Choi Yoon Seok , Shin Eui-Cheol
Published: April 2023

Legend for supplementary data
Table S6 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
Authors: Buhl Juliane L. , Selt Florian , Hielscher Thomas , Guiho Romain , Ecker Jonas , Sahm Felix , Ridinger Johannes , Riehl Dennis , Usta Diren , Ismer Britta , Sommerkamp Alexander C. , Martinez-Barbera J.P. , Wefers Annika K. , Remke Marc , Picard Daniel , Pusch Stefan , Gronych Jan , Oehme Ina , van Tilburg Cornelis M. , Kool Marcel , Kuhn Daniela , Capper David , von Deimling Andreas , Schuhmann Martin U. , Herold-Mende Christel , Korshunov Andrey , Brummer Tilman , Pfister Stefan M. , Jones David T.W. , Witt Olaf , Milde Till
Published: April 2023

Uni-and multivariate Analysis of IL1B and SASP in PA cohort
Table S5 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
Authors: Buhl Juliane L. , Selt Florian , Hielscher Thomas , Guiho Romain , Ecker Jonas , Sahm Felix , Ridinger Johannes , Riehl Dennis , Usta Diren , Ismer Britta , Sommerkamp Alexander C. , Martinez-Barbera J.P. , Wefers Annika K. , Remke Marc , Picard Daniel , Pusch Stefan , Gronych Jan , Oehme Ina , van Tilburg Cornelis M. , Kool Marcel , Kuhn Daniela , Capper David , von Deimling Andreas , Schuhmann Martin U. , Herold-Mende Christel , Korshunov Andrey , Brummer Tilman , Pfister Stefan M. , Jones David T.W. , Witt Olaf , Milde Till
Published: April 2023

IPA upstream regulators
Figure S7 from Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Authors: Hammerl Dora , Massink Maarten P.G. , Smid Marcel , van Deurzen Carolien H.M. , Meijers-Heijboer Hanne E.J. , Waisfisz Quinten , Debets Reno , Martens John W.M.
Published: April 2023

Figure S7. Sets of immune genes show similar levels of expression between molecular (AIMS) and histological subtypes (hormone receptors). A. selected gene-sets associated with immune response. B. selected gene-sets associated with immune suppression (n=247, cohort A).
Figure S4 from Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Authors: Hammerl Dora , Massink Maarten P.G. , Smid Marcel , van Deurzen Carolien H.M. , Meijers-Heijboer Hanne E.J. , Waisfisz Quinten , Debets Reno , Martens John W.M.
Published: April 2023

Figure S4. Prognostic value of TIL signature in LNN BC. A, Kaplan-Meier curves of estimated MFS for patients in Cohort A, discovery set (n=344, p=0.009). B, Kaplan-Meier curves of estimated MFS for patients in Cohort A, validation set (n=523, p=0.016).
Figure S3 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Authors: Courtney Kevin D. , Ma Yuanqing , Diaz de Leon Alberto , Christie Alana , Xie Zhiqun , Woolford Layton , Singla Nirmish , Joyce Allison , Hill Haley , Madhuranthakam Ananth J. , Yuan Qing , Xi Yin , Zhang Yue , Chang Jenny , Fatunde Oluwatomilade , Arriaga Yull , Frankel Arthur E. , Kalva Sanjeeva , Zhang Song , McKenzie Tiffani , Reig Torras Oscar , Figlin Robert A. , Rini Brian I. , McKay Renée M. , Kapur Payal , Wang Tao , Pedrosa Ivan , Brugarolas James
Published: April 2023

Supplementary Figure S3. HIF-2a resistance mutation in Pt35 metastasis progressing on PT2385.
Supplementary Table 2 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Authors: Teixeira Luis , Medioni Jacques , Garibal Julie , Adotevi Olivier , Doucet Ludovic , Durey Marie-Agnès Dragon , Ghrieb Zineb , Kiladjian Jean-Jacques , Brizard Mara , Laheurte Caroline , Wehbe Maria , Pliquet Elodie , Escande Marie , Defrance Rémy , Culine Stephane , Oudard Stephane , Wain-Hobson Simon , Doppler Valérie , Huet Thierry , Langlade-Demoyen Pierre
Published: April 2023

Histological diagnosis, age, number of cycles received and Overall Survival
Supplementary Figure 3 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Authors: Teixeira Luis , Medioni Jacques , Garibal Julie , Adotevi Olivier , Doucet Ludovic , Durey Marie-Agnès Dragon , Ghrieb Zineb , Kiladjian Jean-Jacques , Brizard Mara , Laheurte Caroline , Wehbe Maria , Pliquet Elodie , Escande Marie , Defrance Rémy , Culine Stephane , Oudard Stephane , Wain-Hobson Simon , Doppler Valérie , Huet Thierry , Langlade-Demoyen Pierre
Published: April 2023

Immunophenotyping of circulating CD4 and CD8 T cells
Supplementary Figures and Tables from Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer
Authors: Hu-Lieskovan Siwen , Lisberg Aaron , Zaretsky Jesse M. , Grogan Tristan R. , Rizvi Hira , Wells Daniel K. , Carroll James , Cummings Amy , Madrigal John , Jones Benjamin , Gukasyan Jacklin , Shintaku I. Peter , Slamon Dennis , Dubinett Steven , Goldman Jonathan W. , Elashoff David , Hellmann Matthew D. , Ribas Antoni , Garon Edward B.
Published: April 2023

Supplemental Figure 1. Schematic presentation of the analyzed parameters in the correlative cohort per progression survival (PFS). TMB: total mutational burden. PR: partial response. SD: stable disease. PD: progressive disease. â-³: mutation. Supplemental Figure 2. Progression Free Survival (PFS) and subgroup survival analysis of the correlative cohort (N=38) by Log-rank (Mantel-Cox) test. PFS By PD-L1 categories ( 0-49% n=23 vs 50-100% n=9, p<0.001) PFS By TMB percentile (<25th percentile n=6 vs 25-50th percentile n=7 vs 50-75th percentile n=6 vs >75th percentile n=6, p=0.142) PFS By CD8 categories (0-5% n=18 vs 6-25% n=14, p=0.037) PFS By CD4 categories (0-5% n=21 vs 6-25% n=9 vs >25% n=2, p=0.123) Supplemental Figure 3. Association among the four correlative parameters. Supplemental Table 1. Association of the four correlative parameters and with other clinical characteristics. Supplemental Table 2. Correlation of patient characteristics and ORR per irRC (PR vs SD/PD). Supplemental Table 3. Patient characteristics (as categorical variables) in the correlative cohort per prior lines of therapy. Supplemental Table 4. PFS and OS of correlative characteristics (as categorical variables) by year. Supplemental Table 5. Characteristics as continuous variables of long term benefiters (Overall survival > 3 years with no intervening therapies) vs all other patients in the correlative cohort.
Supplementary Data from Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab
Authors: Magbanua Mark Jesus M. , Savenkov Oleksandr , Asmus Erik J. , Ballman Karla V. , Scott Janet H. , Park John W. , Dickler Maura , Partridge Ann , Carey Lisa A. , Winer Eric P. , Rugo Hope S.
Published: April 2023

TS1-4
Table S3 from Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics
Authors: Yim John H. , Choi Audrey H. , Li Arthur X. , Qin Hanjun , Chang Sue , Tong Sun-Wing T. , Chu Peiguo , Kim Byung-Wook , Schmolze Daniel , Lew Ryan , Ibrahim Yasmine , Poroyko Valeriy A. , Salvatierra Sylvana , Baker Alysha , Wang Jinhui , Wu Xiwei , Pfeifer Gerd P. , Fong Yuman , Hahn Maria A.
Published: April 2023

Molecular and cellular functions associated with genes containing DDMS locations according to Ingenuity® Pathway Analysis (Qiagen Inc.).
Figure S4 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Authors: Lorch Gwendolen , Sivaprakasam Karthigayini , Zismann Victoria , Perdigones Nieves , Contente-Cuomo Tania , Nazareno Alexandra , Facista Salvatore , Wong Shukmei , Drenner Kevin , Liang Winnie S. , Amann Joseph M. , Sinicropi-Yao Sara L. , Koenig Michael J. , La Perle Krista , Whitsett Timothy G. , Murtaza Muhammed , Trent Jeffrey M. , Carbone David P. , Hendricks William P.D.
Published: April 2023

Comparison of HER2 mutant allele fractions measured using droplet digital PCR and targeted sequencing in tumor tissue. HER2V659E was evaluated by ddPCR in tumor DNA samples in which these mutations were also detected using amplicon sequencing. We observed a high correlation between allele fractions measured using both techniques (Pearson's r 0.976, p=0.0008).
Figure S1a from The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients
Authors: Vozenin Marie-Catherine , De Fornel Pauline , Petersson Kristoffer , Favaudon Vincent , Jaccard Maud , Germond Jean-François , Petit Benoit , Burki Marco , Ferrand Gisèle , Patin David , Bouchaab Hanan , Ozsahin Mahmut , Bochud François , Bailat Claude , Devauchelle Patrick , Bourhis Jean
Published: April 2023

Figure S1: A- Serial pictures showing evolution of the mini-pig's skin over time post FLASH and Conv-RT. Three doses are shown (28-34Gy) 24h to 32 weeks post-RT.
Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Authors: Mato Anthony R. , Roeker Lindsey E. , Jacobs Ryan , Hill Brian T. , Lamanna Nicole , Brander Danielle , Shadman Mazyar , Ujjani Chaitra S. , Yazdy Maryam Sarraf , Perini Guilherme Fleury , Pinilla-Ibarz Javier A. , Barrientos Jacqueline , Skarbnik Alan P. , Torka Pallawi , Pu Jeffrey J. , Pagel John M. , Gohil Satyen , Fakhri Bita , Choi Michael , Coombs Catherine C. , Rhodes Joanna , Barr Paul M. , Portell Craig A. , Parry Helen , Garcia Christine A. , Whitaker Kate J. , Winter Allison M. , Sitlinger Andrea , Khajavian Sirin , Grajales-Cruz Ariel F. , Isaac Krista M. , Shah Pratik , Akhtar Othman S. , Pocock Rachael , Lam Kentson , Voorhees Timothy J. , Schuster Stephen J. , Rodgers Thomas D. , Fox Christopher P. , Martinez-Calle Nicolas , Munir Talha , Bhavsar Erica B. , Bailey Neil , Lee Jason C. , Weissbrot Hanna B. , Nabhan Chadi , Goodfriend Julie M. , King Amber C. , Zelenetz Andrew D. , Dorsey Colleen , Bigelow Kayla , Cheson Bruce D. , Allan John N. , Eyre Toby A.
Published: April 2023

Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.
Supplementary Data from DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling
Authors: Li Jie , Pan Chaoyun , Boese Austin C. , Kang JiHoon , Umano Anna D. , Magliocca Kelly R. , Yang Wenqing , Zhang Yu , Lonial Sagar , Jin Lingtao , Kang Sumin
Published: April 2023

Supplementary Fig S1
Supplementary Data from DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling
Authors: Li Jie , Pan Chaoyun , Boese Austin C. , Kang JiHoon , Umano Anna D. , Magliocca Kelly R. , Yang Wenqing , Zhang Yu , Lonial Sagar , Jin Lingtao , Kang Sumin
Published: April 2023

Supplementary Table S1
Supplementary Data from Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
Authors: Dillon Magnus T. , Grove Lorna , Newbold Kate L. , Shaw Heather , Brown Nicholas F. , Mendell Jeanne , Chen Shuquan , Beckman Robert A. , Jennings Anne , Ricamara Marivic , Greenberg Jonathan , Forster Martin , Harrington Kevin J.
Published: April 2023

Tables S1, S2, S3, S4, S5
Figure S13 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Figure S13
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Authors: Jaeger Alex M. , Stopfer Lauren , Lee Sunmin , Gaglia Giorgio , Sandel Demi , Santagata Sandro , Lin Nancy U. , Trepel Jane B. , White Forest , Jacks Tyler , Lindquist Susan , Whitesell Luke
Published: April 2023

HSP990 MS Data
Table S2 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Authors: Zhou Rong , Shi Chaoji , Tao Wenjie , Li Jiang , Wu Jing , Han Yong , Yang Guizhu , Gu Ziyue , Xu Shengming , Wang Yujue , Wang Lizhen , Wang Yanan , Zhou Guoyu , Zhang Chenping , Zhang Zhiyuan , Sun Shuyang
Published: April 2023

Significantly mutated genes,promoters and UTRs of MMs.
Supplementary Tables 1-7 from Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Authors: Pozdeyev Nikita , Gay Laurie M. , Sokol Ethan S. , Hartmaier Ryan , Deaver Kelsi E. , Davis Stephanie , French Jena D. , Borre Pierre Vanden , LaBarbera Daniel V. , Tan Aik-Choon , Schweppe Rebecca E. , Fishbein Lauren , Ross Jeffrey S. , Haugen Bryan R. , Bowles Daniel W.
Published: April 2023

Supplementary Table 1. MSK-IMPACT and FoundationOne thyroid cancer cohorts. Supplementary Table 2. Genes analyzed by MSK-IMPACT and FoundationOne panels and gene assignments into the annotation groups. Supplementary Table 3. Annotated list of genetic alterations reported by MSK-IMPACT and FoundationOne. Supplementary Table 4. Mutation-high thyroid cancers, mutation classes and mutation signatures. Supplementary Table 5. BRAF, RET, NTRK1, NTRK3 and ALK fusion partners. Supplementary Table 6. Gene alteration associations in ATC. Supplementary Table 7. Genes with high proportion of frameshift, nonsense and spice site mutations.
Supplementary Figure 4 from Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Authors: Pozdeyev Nikita , Gay Laurie M. , Sokol Ethan S. , Hartmaier Ryan , Deaver Kelsi E. , Davis Stephanie , French Jena D. , Borre Pierre Vanden , LaBarbera Daniel V. , Tan Aik-Choon , Schweppe Rebecca E. , Fishbein Lauren , Ross Jeffrey S. , Haugen Bryan R. , Bowles Daniel W.
Published: April 2023

Genetic alterations in follicular thyroid cancer
Supplementary Data from Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial
Authors: Wang Shuhong , Lin Yusheng , Xiong Xiao , Wang Lu , Guo Yi , Chen Yuping , Chen Shaobin , Wang Geng , Lin Peng , Chen Hongcai , Yeung Sai-Ching Jim , Bremer Edwin , Zhang Hao
Published: April 2023

Supplementary data including supplementary materials and methods.
Figure S3 from Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Authors: Gris-Oliver Albert , Palafox Marta , Monserrat Laia , Brasó-Maristany Fara , Òdena Andreu , Sánchez-Guixé Mònica , Ibrahim Yasir H. , Villacampa Guillermo , Grueso Judit , Parés Mireia , Guzmán Marta , Rodríguez Olga , Bruna Alejandra , Hirst Caroline S. , Barnicle Alan , de Bruin Elza C. , Reddy Avinash , Schiavon Gaia , Arribas Joaquín , Mills Gordon B. , Caldas Carlos , Dienstmann Rodrigo , Prat Aleix , Nuciforo Paolo , Razavi Pedram , Scaltriti Maurizio , Turner Nicholas C. , Saura Cristina , Davies Barry R. , Oliveira Mafalda , Serra Violeta
Published: April 2023

Low pAkt S473 is associated with resistance to AZD5363 monotherapy
Figure S1 from Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Authors: Gris-Oliver Albert , Palafox Marta , Monserrat Laia , Brasó-Maristany Fara , Òdena Andreu , Sánchez-Guixé Mònica , Ibrahim Yasir H. , Villacampa Guillermo , Grueso Judit , Parés Mireia , Guzmán Marta , Rodríguez Olga , Bruna Alejandra , Hirst Caroline S. , Barnicle Alan , de Bruin Elza C. , Reddy Avinash , Schiavon Gaia , Arribas Joaquín , Mills Gordon B. , Caldas Carlos , Dienstmann Rodrigo , Prat Aleix , Nuciforo Paolo , Razavi Pedram , Scaltriti Maurizio , Turner Nicholas C. , Saura Cristina , Davies Barry R. , Oliveira Mafalda , Serra Violeta
Published: April 2023

Response to AZD5363 in PDX models recapitulates patients' response
Supplementary Figure S1-S15 from Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo–Expanded Autologous NK Cells
Authors: Wang Yufeng , Zhang Yibo , Hughes Tiffany , Zhang Jianying , Caligiuri Michael A. , Benson Don M. , Yu Jianhua
Published: April 2023

Supplementary Figure S1: Dara induces IFN-gamma expression in primary human NK cells; Supplementary Figure S2: MM.1S surface expression of CD38 was assessed by flow cytometry; Supplementary Figure S3: Dara promotes NK-mediated ADCC of MM.1S target cells, which correlates to activation of STAT1 and NF-kB signaling; Supplementary Figure S4: Dara fails to increase apoptosis or IFNG expression in CD16(-) NK-92 cells; Supplementary Figure S5: Reduction in relative proportion of NK cells occurs in both peripheral blood and bone marrow of Dara-treated MM patients; Supplementary Figure S6: Dara increases primary NK cell death; Supplementary Figure S7: Separation of daratumumab into F(ab')2 and Fc fragments; Supplementary Figure S8: CD38^â^'/low primary NK cells show lower apoptotic activity than CD38^+ primary NK cells; Supplementary Figure S9: Compared to their CD38^+ counterparts, the CD38^â^'/low subset of NK cells from peripheral blood of healthy donors are more proliferative and have higher levels of cytotoxicity against MM targets; Supplementary Figure S10: Competition between CD38^+ exp. NK cells and MM cells for Dara binding during co-culture; Supplementary Figure S11: Differential expression of surface receptors within CD38^+ and CD38^â^'/low subsets of NK cells; Supplementary Figure S12: Differential expression of GZMB in CD38^+ and CD38^â^'/low NK subsets found within populations of CD56^bright and CD56^dim NK cells; Supplementary Figure S13: Purity of in vitro-expanded NK cells at day 7; Supplementary Figure S14: NK cells expanded (eNK) from Dara-treated MM patient PBMCs show anti-tumor efficacy against MM in an in vivo mouse model; Supplementary Figure S15: Treatment of MM-bearing mice with or without Dara, expanded NK cells (eNK), or their combination.
Supplemental Table 3 from Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity
Authors: Bodelon Clara , Killian J. Keith , Sampson Joshua N. , Anderson William F. , Matsuno Rayna , Brinton Louise A. , Lissowska Jolanta , Anglesio Michael S. , Bowtell David D.L. , Doherty Jennifer A. , Ramus Susan J. , Talhouk Aline , Sherman Mark E. , Wentzensen Nicolas
Published: April 2023

Supplemental Table 3
Supplementary Data from Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Authors: Bekaii-Saab Tanios , Wesolowski Robert , Ahn Daniel H. , Wu Christina , Mortazavi Amir , Lustberg Maryam , Ramaswamy Bhuvaneswari , Fowler Jeffrey , Wei Lai , Overholser Jay , Kaumaya Pravin T.P.
Published: April 2023

This file contains supplemental materials, tables, and figures.